Author Archive for: sarah-lanford
About Sarah Lanford
Sarah Lanford joined NASHP in August 2018. As a policy associate, she works with the Coverage, Cost, and Value team, and projects related to prescription drug costs. Before joining NASHP, Sarah worked at Stateside Associates, where she monitored and analyzed state health policy legislation. She has also worked for the Texas Democratic Party and the Texas State Senate, and served as a page in the United States Senate. She holds a BA in government from the University of Texas at Austin.
Entries by Sarah Lanford
NASHP’s Annual Conference Highlights States Taking Bold Action on Drug Prices
October 20, 2021 in Prescription Drug Pricing Featured News Home Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Sarah Lanford and Jennifer ReckWhile Congress continues to consider significant reforms for drug pricing, states have taken bold steps to control drug prices across payers. This legislative session, Colorado followed Maryland’s lead and established a prescription drug affordability board (PDAB) to address high drug prices. PDAB legislation, such as Maryland’s and Colorado’s, that includes authority for a board to […]
2021 State Legislative Session Recap on States’ Efforts to Lower Drug Costs
August 2, 2021 in Prescription Drug Pricing Blogs, Featured News Home /by Sarah LanfordFor many states, the 2021 legislative session has ended. During this past session, 20 states enacted 43 laws to address rising drug costs, an increase from the 17 states that enacted 41 laws last year, despite states’ ongoing focus on COVID-19. Enacted state laws include establishing a prescription drug affordability board (PDAB), limiting patients’ out-of-pocket insulin costs, regulating pharmacy benefit managers (PBMs), and requiring transparency from entities throughout the pharmaceutical supply chain. Colorado’s Prescription Drug Affordability Board (PDAB) […]
Will Laws to Lower Drug Prices Harm Innovation? The Evidence Says No.
March 8, 2021 in Prescription Drug Pricing Blogs, Featured News Home Administrative Actions, Consumer Affordability, Health System Costs, Legal Resources, Making the Case for Action, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Sarah LanfordDrug makers claim high prices are necessary to support new drug development and innovation, but research shows that public investment in drug research and development combined with large industry profits leaves manufacturers room to lower prices while continuing to innovate.
Eye on the Storm: Two NASHP Staffers in Texas Reflect on Weathering Winter Storm Uri
March 1, 2021 in Policy Texas Blogs, Featured News Home COVID-19, Health Equity, Housing and Health, Population Health, Social Determinants of Health /by Eskedar Girmash and Sarah LanfordLast month, Winter Storm Uri caused catastrophic power outages across Texas. National Academy for State Health Policy staff Eskedar Girmash and Sarah Lanford, who work remotely from Dallas and Houston during the pandemic, were both without power for four days as temperatures fell to single digits and they lost access to water. At least 58 people died trying to stay warm, and more […]
Supreme Court Hears Arkansas Pharmacy Benefit Manager Challenge Today
October 5, 2020 in Policy Arkansas Blogs, Featured News Home Administrative Actions, Legal Resources, Prescription Drug Pricing, State Rx Legislative Action /by Sarah Lanford and Jennifer ReckToday, the US Supreme Court is scheduled to hear oral arguments in a legal challenge of an Arkansas law that regulates the reimbursement rates that pharmacy benefit managers (PBMs) pay to pharmacies.
States Act to Protect Consumers against Unproven COVID-19 Drugs and Safeguard Supplies as FDA Approves Limited Use
March 30, 2020 in COVID-19 State Action Center Blogs, Featured News Home Administrative Actions, Consumer Affordability, COVID-19, Health System Costs, Prescription Drug Pricing /by Trish Riley and Sarah LanfordAt least 11 states have acted to limit the dispensing of chloroquine and hydroxychloroquine – prescription drugs that have been cited as providing protection against coronavirus (COVID-19) without adequate clinical evidence to support that claim. To protect consumers with or at risk of COVID-19 and to prevent stockpiling of these drugs, which treat malaria, rheumatoid […]
Proposed Rule Could Save Consumers Millions by Changing the Insurer-PBM Relationship, Comments Due March 2
February 24, 2020 in Policy Blogs, Featured News Home Administrative Actions, Health Coverage and Access, Prescription Drug Pricing, State Insurance Marketplaces, State Rx Legislative Action /by Sarah Lanford and Maureen Hensley-QuinnSign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 























































































































































